GeoVax was using its HHS contract to develop its next-generation multi-antigen COVID-19 vaccine, which is in Phase IIb ...

Despite the PNG award termination, GeoVax anticipates a milestone-rich 2025 across its portfolio. The Company will continue to engage with government and industry partners, pursue clinical trial ...

The U.S. government continues to end contracts related to the $5 billion Project NextGen initiative, this time terminating ...

GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and cancer, today announced the publication of a peer ...

D. Boral Capital lowered the firm’s price target on GeoVax Labs (GOVX) to $14 from $18 and keeps a Buy rating on the shares.

Oncology, and Biosecurity Amid Strategic Program Developments ATLANTA, GA - April 16, 2025 (NEWMEDIAWIRE) - GeoVax Labs, Inc.

In a regulatory filing earlier, GeoVax disclosed that on April 11, the company received written notification from Advanced Technology ...

Citigroup Inc. C +3.20% + Free Alerts posted better-than-expected earnings for its first quarter. Citigroup reported quarterly earnings of $1.96 per share which beat the analyst consensus estimate of ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on GeoVax Labs (GOVX – Research Report), Tango Therapeutics (TNGX – Research Repo ...

U.S. stocks traded higher this morning, with the Nasdaq Composite gaining around 100 points on Tuesday. Following the market opening Tuesday, the Dow traded up 0.41% to 40,689.26 while the NASDAQ ...

Get Our Latest Report on GOVX GeoVax Labs Price Performance NASDAQ GOVX opened at $1.08 on Wednesday. The company has a market cap of $10.19 million, a P/E ratio of -0.19 and a beta of 3.06 ...

Upgrade to begin using 40 years of financial statements and get so much more. Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.